Publication | Closed Access

Galantamine-induced improvements in cognitive function are not related to alterations in α4β2 nicotinic receptors in early Alzheimer’s disease as measured in vivo by 2-[18F]Fluoro-A-85380 PET

Neurodegenerative DiseasesAlzheimer's DiseaseSynaptic SignalingCognitive PerformanceMedicineNeuropharmacologyCognitive FunctionNeurologyNeuroscienceα4β2 Nicotinic ReceptorsMolecular NeurobiologyPharmacologyNeurochemistryGalantamine-induced ImprovementsHealth Sciences